2-氨基-6-羟基-5-(1-甲基乙基)-4(1H)-嘧啶酮 | 500161-23-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-6-羟基-5-(1-甲基乙基)-4(1H)-嘧啶酮
• 中文别名: 10-甲氧基-4-(1-甲基哌啶-4-基)-4H-苯并[4.5]环庚三烯并[1,2-b]噻吩-4-醇
• 英文名称: 2-amino-5-isopropylpyrimidine-4,6-diol
• 英文别名: 2-Amino-4,6-dihydroxy-5-isopropylpyrimidine；2-amino-4-hydroxy-5-propan-2-yl-1H-pyrimidin-6-one
• CAS: 500161-23-9
• 化学式: C₇H₁₁N₃O₂
• 分子量: 169.183
• InChiKey: GWBXUTJCYUUSDY-UHFFFAOYSA-N

物化性质

• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 储存条件：
  室温且干燥

反应信息

• 作为反应物：
  描述：

  2-氨基-6-羟基-5-(1-甲基乙基)-4(1H)-嘧啶酮 在 盐酸 、 水 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 6.0h， 生成 2-氨基-4,6-二氯-5-异丙基嘧啶
  参考文献：
  名称：

  5-Substituted 2-amino-4,6-dihydroxypyrimidines and 2-amino-4,6-dichloropyrimidines: synthesis and inhibitory effects on immune-activated nitric oxide production

  摘要：

  A series of 5-substituted 2-amino-4,6-dihydroxypyrimidines were prepared by a modified condensation of the corresponding monosubstituted malonic acid diesters with guanidine in an excess of sodium ethoxide. The optimized procedure using Vilsmeier-Haack-Arnold reagent, followed by immediate deprotection of the (dimethylamino)methylene protecting groups, has been developed to convert the 2-amino-4,6-dihydroxypyrimidine analogs to novel 5-substituted 2-amino-4,6-dichloropyrimidines in high yields. Pilot screening for biological properties of the prepared compounds was done in mouse peritoneal cells using the in vitro nitric oxide (NO) assay. Irrespective of the substituent at the 5 position, 2-amino-4,6-dichloropyrimidines inhibited immune-activated NO production. The most effective was 5-fluoro-2-amino-4,6-dichloropyrimidine with an IC ₅₀ of 2 µM (higher activity than the most potent reference compound) while the IC ₅₀s of other derivatives were within the range of 9-36 µM. The 2-amino-4,6-dihydroxypyrimidine counterparts were devoid of any NO-inhibitory activity. The compounds had no suppressive effects on the viability of cells. The Mechanism of action remains to be elucidated.

  DOI：

  10.1007/s00044-014-1018-9
• 作为产物：
  描述：

  盐酸胍 、 异丙基丙二酸二乙酯 在 sodium 作用下， 以 乙醇 为溶剂， 反应 0.08h， 生成 2-氨基-6-羟基-5-(1-甲基乙基)-4(1H)-嘧啶酮
  参考文献：
  名称：

  [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  [FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE

  摘要：

  本公开提供囊性纤维化跨膜传导调节因子（CFTR）的调节剂，其具有以下核心结构：，包含至少一种这样的调节剂的药物组合物，使用这样的调节剂和药物组合物治疗CFTR介导的疾病，包括囊性纤维化的方法，使用这些调节剂的组合疗法和组合药物，以及制造这些调节剂的过程和中间体。

  公开号：

  WO2022076627A1

文献信息

• [EN] PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF<br/>[FR] COMPOSÉS DE PYRIMIDINE INHIBANT LA FORMATION D'OXYDE NITRIQUE ET PROSTAGLANDINE E2, LEUR PROCÉDÉ DE PRODUCTION ET LEUR UTILISATION
  申请人：USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR V V I

  公开号：WO2012116666A1

  公开（公告）日：2012-09-07

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.˙

  该发明提供了一般式(I)的嘧啶化合物，可以同时减少一氧化氮（NO）和前列腺素E2（PGE2）的产生。它们在降低这些因子产生达到50%的浓度下对细胞的存活性没有负面影响；它们不具有细胞毒性。此外，还提供了一种制备一般式(I)的带有2-甲酰胺基团的嘧啶化合物的方法，一种包括根据该发明的取代嘧啶化合物的药物组合物，以及利用这些化合物治疗炎症和癌症疾病的方法。
• PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF
  申请人：Ustav Organicke Chemie a Biochemie Akademie Ved CR, v.v.i.

  公开号：US20130324566A1

  公开（公告）日：2013-12-05

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.

  本发明提供了一种通式（I）的嘧啶化合物，它们能同时减少一氧化氮（NO）和前列腺素E2（PGE2）的产生。它们在浓度减少这些因子的产生高达50％时，对细胞的生存能力没有负面影响，也不具有细胞毒性。此外，本发明还提供了一种制备带有2-甲酰胺基团的嘧啶化合物的方法，以及包含根据本发明所述的取代嘧啶化合物的制药组合物，以及使用这些化合物治疗炎症和癌症疾病的方法。
• ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES
  申请人：BioCryst Pharmaceuticals, Inc.

  公开号：US20170267681A1

  公开（公告）日：2017-09-21

  Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.
• US8883798B2
  申请人：——

  公开号：US8883798B2

  公开（公告）日：2014-11-11